Additionally, the FDA has approved B cell maturation antigen (BCMA)-targeted CAR-T cells for relapsed/refractory multiple myeloma, which have shown overall response rates of 73–98% [31,32]. The gene discussed is TNFRSF17; the disease is AL amyloidosis.